Sedivention secures €2.9M seed financing to advance outpatient obesity therapy
NOME portfolio company Sedivention has closed a €2.9 million seed financing round to further develop its minimally invasive, outpatient therapy for the treatment of obesity. The round includes participation from High‑Tech Gründerfonds (HTGF) alongside other investors, and will support continued ...